Fairmount Funds Management LLC
Fairmount Funds Management LLC reported 12 holdings worth US$1.59B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Fairmount Funds Management LLC reported 12 holdings worth US$1.59B as of Sep 30, 2026. Largest: Oruka Therapeutics, Inc., Dianthus Therapeutics, Inc. and Cogent Biosciences, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 12
- Value as reported
- US$1.59B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Oruka Therapeutics, Inc. | 3.71M | US$309M | 19.4% |
| Dianthus Therapeutics, Inc. | 2.54M | US$223M | 14.0% |
| Cogent Biosciences, Inc. | 5.5M | US$176M | 11.1% |
| Viridian Therapeutics, Inc. | 5.09M | US$105M | 6.6% |
| Enliven Therapeutics, Inc. | 1.86M | US$85.1M | 5.3% |
| Jade Biosciences, Inc. | 4.55M | US$64M | 4.0% |
| Zenas BioPharma, Inc. | 2.37M | US$64M | 4.0% |
| Crescent Biopharma, Inc. | 3.6M | US$52.5M | 3.3% |
| Sensei Biotherapeutics, Inc. | 722K | US$21.5M | 1.3% |
| Inhibikase Therapeutics, Inc. | 8.63M | US$17.7M | 1.1% |
| Apogee Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Damora Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC